Skip to main content

Advertisement

Lung cancer

Edited by Lin Yan and Wei Zhang

Lung cancer, the most prevalent and deadly malignancy, accounts for a staggering 1.6 million new cases diagnosed every year and approximately 21% of cancer deaths to the global cancer burden. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking, with an estimated 733,280 new cases every year and 671,625 deaths.

This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development for lung cancer, showcases the first wave of innovation and analyzes the unique challenges in developing novel drugs for lung cancer in China, as well as rolling out a global effort to address these challenges.

  1. Review

    Global efforts in conquering lung cancer in China

    Lung cancer, the most prevalent and deadly malignancy in the world, poses a particularly critical healthcare challenge to China due to the rapidly increasing new cases and the unique cancer genetics in Chinese...

    Li Yan and Li Xu

    Chinese Journal of Cancer 2015 34:32

    Published on: 28 July 2015

  2. Original article

    Insight into early-phase trials for lung cancer in the United States

    Few data have been published comparing early-phase trials for lung cancer between China and the United States (US). This study was to investigate the differences of phase 1 trials for lung cancer between these...

    Jin-Ji Yang and Yi-Long Wu

    Chinese Journal of Cancer 2015 34:29

    Published on: 10 July 2015

  3. Perspective

    Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance

    Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in ...

    Xiao Xu

    Chinese Journal of Cancer 2015 34:27

    Published on: 8 July 2015

Advertisement